Aerubumab

N/A

Report date: 2024/04/25 20:00:07

Base Information

Drug NameAerubumab
Drug Alias NameaerubumabAerucinCM-101 (Aridis Pharmaceuticals)F-429AR-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionBacterial polysaccharides inhibitors
TargetsBacterial polysaccharides
Therapy Area/IndicationsPseudomonas aeruginosa pneumonia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[17] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSerum Institute Of India Pvt LtdAridis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPseudomonas aeruginosa pneumonia

Other Information

ATC CodeN/A
Related LinksN/A